TrialClinical epigenetics2022

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.

Thatcher R Heumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.